Nasdaq · Healthcare
Amneal Pharmaceuticals, Inc. (AMRX)
As-reported financials and recent SEC filings for Amneal Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.02B
Net income
$72.1M
Net margin
2.4%
Diluted EPS
$0.22
ROE
-101.0%
P/E (TTM)
46.6×
Market cap
$5.50B
Debt / equity
-36.0×
Income statement (as reported)
| Line | FY2025 | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Gross profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M |
| Operating income | $394.1M | $249.3M | $204.4M | $-94.9M | $152.7M |
| Net income | $72.1M | $-116.9M | $-84.0M | $-270.6M | $13.2M |
| Diluted EPS | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
PREM14A2026-06-18
View on EDGAR →42026-05-12
View on EDGAR →1442026-05-11
View on EDGAR →42026-05-08
View on EDGAR →42026-05-08
View on EDGAR →42026-05-08
View on EDGAR →42026-05-08
View on EDGAR →42026-05-08
View on EDGAR →Go deeper on AMRX
Search Amneal Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.